Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
2026年8月10日 更新者：Natalie S. McAndrew, PhD, RN、Mayo Clinic
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant.
MCP-Dyad is a meaning-focused support program.
It is designed to help people stay connected to meaning, cope with difficult experiences, and communicate as a pair during recovery.
調査の概要
研究の種類
介入
入学 (推定)
100
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Study Team
- 電話番号：507-422-5523
- メール：rstnursingresearch@mayo.edu
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
コンタクト：
- Study Team
- 電話番号：507-422-5523
- メール：rstnursingresearch@mayo.edu
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion criteria:
- Eligible patients and their caregivers must be adults (≥18 years)
- Patient must have undergone HSCT for a malignant blood cancer condition
- Caregiver must be the main support person (e.g., signed caregiving contract) for the HSCT patient
- Both the patient and their caregiver must be willing to participate in the study (dyads only)
- Be able to read, write, and speak in English
- Have access to a smartphone, computer, or tablet necessary for study participation and assessments. If a patient/caregiver dyad is interested in participating but does not have such a device, we will provide a Tracfone with smartphone capabilities for each member of the dyad
Exclusion criteria:
- Patients undergoing HSCT for nonmalignant conditions
- Patients and caregivers with severe cognitive or psychiatric impairment that may affect informed consent/participation
- Prisoners, pregnant women, and institutionalized persons
- Patients with severe cognitive or psychiatric impairment that would affect informed consent or participation
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Meaning-Centered Psychotherapy (MCP) Dyad
The MCP-Dyad arm participants will meet with an MCP-Dyad interventionist to engage in didactic content, reflection, and discussion to teach participants how to apply four sources of meaning to their lives
|
Survivor and caregiver dyads will participate in a seven-session, telehealth delivered Meaning-Centered Psychotherapy for Dyads (MCP-Dyad) program post-transplant.
|
|
アクティブコンパレータ：Usual Care
The standard of care arm will receive standard resources and consultations for HSCT care, which include a joint educational class for patients and caregivers before and after treatment.
|
Survivor and caregiver dyads will receive standard resources and consultations for hematopoietic stem cell transplantation (HSCT) care, which include a joint educational class for patients and caregivers before and after treatment.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MCP-Dyad acceptability as rated on the Acceptability of Intervention Measure (AIM)
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Acceptability of Intervention Measure (AIM) questionnaire (benchmark: 70%).
Higher scores signify greater agreement with intervention acceptability.
|
End of treatment (approximately 14 weeks)
|
|
Feasibility to accrue HSCT patient/caregiver dyads
時間枠：2 years
|
Percentage of eligible caregivers approached who consent and enroll within 24 months.
|
2 years
|
|
MCP-Dyad intervention completion
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of patients and caregivers in the MCP-Dyad cohort who complete at least 5 out of 7 intervention sessions (benchmark: 70%).
|
End of treatment (approximately 14 weeks)
|
|
MCP-Dyad Feasibility rating from participants (Feasibility of Intervention Measure-FIM)
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of patients and caregivers who rate MCP-Dyad as 4/5 or higher on the Feasibility of Intervention Measure (FIM) 4-item questionnaire (benchmark: 70%).
Higher scores signify greater agreement with intervention feasibility.
|
End of treatment (approximately 14 weeks)
|
|
MCP-Dyad retention
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of randomized dyads with both members completing follow-up assessments (benchmark: 75%).
|
End of treatment (approximately 14 weeks)
|
|
MCP-Dyad intervention fidelity and protocol delivery
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of audited sessions meeting intervention fidelity standards and delivered per protocol based on fidelity assessments (benchmark: ≥80%)
|
End of treatment (approximately 14 weeks)
|
|
MCP-Dyad appropriateness as rated on the Intervention Appropriateness Measure (IAM)
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of patients and caregivers who rate the intervention as 4/5 or higher on the 4-item Intervention Appropriateness Measure (IAM) questionnaire (benchmark: 70%).
Higher scores signify greater agreement with intervention appropriateness.
|
End of treatment (approximately 14 weeks)
|
|
MCP-Dyad dyad-level retention outreach
時間枠：End of treatment (approximately 14 weeks)
|
Percentage of missed sessions or assessments that receive outreach within 2 days (benchmark: ≥85%).
|
End of treatment (approximately 14 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Benefit Finding Scale (BFS) score
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on benefit finding will be measured using a slightly modified version of the Benefit Finding Scale (BFS), a 17-item measure that captures positive life challenges resulting from adversity (e.g., personal priorities, acceptance, daily activities, family, world views, relationship, purpose).
Higher scores indicate greater benefit finding.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in Communal Coping Domains score
時間枠：8 weeks post-intervention
|
The Communal Coping Domains instrument assesses how patients and caregivers manage health-related behavior change, particularly in the context of health threats by measuring shared perceptions, confidence, and behaviors.
There are three tailored subscales: use of communal coping (how frequently dyads use joint efforts to manage health threats), how confident the dyad is in working together to manage health, and beliefs about communal coping strategies.
Responses for the use of the communal coping domain range from 1(never) to 5 (very often), and responses for the couple efficacy and outcome efficacy range from 0 (not at all) to 10 (very much).
Higher overall scores indicate greater confidence in patient/caregiver coping strategies.
|
8 weeks post-intervention
|
|
Change in survivor and caregiver health-related quality of life.
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on patient and caregiver health-related quality of life will be assessed using the Functional Assessment of Cancer Therapy -Bone Marrow Transplant (FACT-BMT).
The patient instrument is a multidimensional measure of quality of life in adult HSCT patients.
Each item is rated from 0 (not at all) to 4 (very much) and is an assessment of symptoms over the past 7 days.
Domains include social and family well-being, emotional well-being, functional well-being, and BMT-specific concerns.
Higher scores overall indicate better quality of life.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in survivor and caregiver existential distress
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on the patient and caregiver's meaning and purpose (increased meaning and purpose equivalent to less existential distress) will be measured using the 48-item Life Attitude Profile-Revised (LAP-R) instrument.
It has six domains (purpose, coherence, life control, death acceptance, existential vacuum, goal seeking) that make up two subscales, the Personal Meaning Index and Existential Transcendence.
Higher scores generally indicate a more positive attitude towards life.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in survivor and caregiver spiritual well-being
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on the patient's and caregiver's spiritual well-being will be measured using the Functional Assessment of Chronic Illness Therapy Spiritual Well-being (FACIT-Sp) Scale.
It has two subscales, one for faith and another for meaning/peace.
Higher scores indicate greater spiritual well-being.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in survivor and caregiver mutuality (quality of relationship)
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on survivor and caregiver mutuality will be measured using Mutuality Scale (MS).
The Mutuality Scale measures the positive quality of the relationship between the care recipient and the caregiver.
Grounded in the concept of mutuality (degree of love, reciprocity, shared pleasurable activities, and shared values) in the patient/caregiver relationship.
There is a four-domain structure with items rated from 0 (not at all) to 4 (a great deal) with question stems examining varies aspects of the relationship (e.g., how much do you enjoy spending time together).
Higher overall scores indicate greater mutuality.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in dyadic adjustment (couples only)
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad in couples will be measured using the Revised Dyadic Adjustment Scale (RDAS).
The RDAS is a self-report measure of relationship quality in couples.
It assesses dyadic consensus, dyadic satisfaction, and dyadic cohesion to give an overall index of marital quality.
The rating scale is 0 (always disagree) to 5 (always agree).
Higher overall scores indicates greater relationship satisfaction.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in illness-related communication
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The change in illness-related communication will be measured using the Social Constraints Scale.
This scale measures the extent to which individuals perceive their social environment, particularly close relationships, as a limiting or discouraging their ability to express thoughts and feelings related to a stressful experience.
Items are rated from 1(never) to 4 (very often).
Higher scores are equivalent to more social constraints in the relationship.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in survivor and caregiver needs/distress
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on the survivor and caregiver's needs/distress will be measured using the Cancer SupportSource Survivors: CCS-15+ and the CancerSupportSource-Caregiver: CCS-Caregiver-18+ instruments.
Survivors and caregivers will rate their level of concern from 0 (not at all) to 4 (very serious concern).
Questions for survivors focus on emotional well-being, symptom burden & impact, body image & healthy lifestyle, health care team communication, relationships & intimacy.
Questions for caregivers focus on 5 areas of concern (emotional well-being, survivor well-being, caregiving tasks, finances, and healthy lifestyle) and areas of desired support.
A total score for distress is recommended based on 18 items.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in survivor and caregiver psychological distress
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The impact of MCP-Dyad on psychological distress will be measured using 2 anxiety and 2 depression questions from the CCS-15+ and the CCS-Caregiver-18+.
These questions have established clinical cut offs.
Scores range from 0 to 8. Survivor scores of 3 or above signify clinically significant anxiety or depression.
Caregiver anxiety scores of 4 and above, and depression scores of 3 or above, indicate clinically significant distress.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in Dyadic Relationship Scale score
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The Dyadic Relationship Scale is a brief dyadic measure assessing positive dyadic interaction and negative dyadic strain from both caregiver and care recipient perspectives.
The caregiver version includes 11 items and the care recipient version includes 10 items, with two subscales: positive dyadic interaction and negative dyadic strain.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
|
Change in interdependence of survivor and caregiver
時間枠：Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
The Inclusion of Other in the Self Scale is a single-item pictorial measure of perceived relationship closeness and self-other overlap.
Respondents select one of seven increasingly overlapping circle pairs to represent their relationship with a specified other person, with higher scores indicating greater perceived closeness.
|
Baseline, End of treatment (approximately 14 weeks), 8 weeks post-intervention
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
捜査官
- 主任研究者：Natalie McAndrew, PhD, RN、Mayo Clinic
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年12月1日
一次修了 (推定)
2028年2月28日
研究の完了 (推定)
2028年4月30日
試験登録日
最初に提出
2026年5月12日
QC基準を満たした最初の提出物
2026年5月12日
最初の投稿 (実際)
2026年5月19日
学習記録の更新
投稿された最後の更新 (実際)
2026年8月12日
QC基準を満たした最後の更新が送信されました
2026年8月10日
最終確認日
2026年8月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 26-005192
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。